... ever direct observations in real-time of the growth
of single nanocrystals in solution, which ... (NCEM), led a team of experts in nanocrystal growth
and electron microscopy who combined their skills to observe the dynamic growth
of colloidal platinum nanocrystals in solution ...
Microbix Sales Grow 22% For Nine Months
... exchange rates. The forecast is for continued growth
"The 22% sales growth
achieved in the nine months ending June 30, 2009 ... revenue in the following six months. We see the growth
trend in product volume enjoyed in 2009 ...
ThermoGenesis Provides Update on Fiscal 2009 Results
... said the following factors are expected to drive growth
and contribute to improved financial performance ... our quality will enable us to focus on our growth
initiatives. We believe through the expansion of ... will be positioned to achieve meaningful growth
in revenues during 2010," Engle added. "We ...
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
... cell responsible for driving tumor initiation, growth
and recurrence. Research published in Cell Stem ... cell pathway impacts tumor cell proliferation, growth
OMP-21M18 is a monoclonal ... that blocks DLL4 signaling to reduce tumor growth
two ways: by reducing cancer stem cell frequency ...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
"We were pleased to observe continued sales growth
in our Proprietary Medical Products business ... that may provide for more substantial revenue growth
potential as compared to our overall product ... Products continued to demonstrate higher revenue growth
as compared to our overall product portfolio, ...
The Breast Cancer Therapeutics Market in Australia
... including Epotheliones and Vascular Endothelial growth
Factor Receptor (VEGFR) inhibitors."
... through our Pharmaceutical & Biotechnology growth
Partnership Services programme. With continuous ... of the Complex Business Universe, the growth
Partnership Services programme ensures that you ...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... $491 million +20%
Product sales growth
(excluding ADDERALL XR) at
constant exchange ... with the same period in 2008.
(2) Sales growth
at constant exchange rates ("CER"), which is a ... XR, of $491 million, representing growth
of 20% compared to the same
quarter last year. ...
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
... company focused on the delivery of nervous system growth
(neurotrophic) factors for the treatment of ... CERE-110, an AAV2 based vector expressing nerve growth
factor that is currently in a multi-center, ... include Alta Partners, MPM Capital, Investor growth
Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) ...
Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
... supporting the use of GAM to deliver bone growth
factors. Cardium believes that future DNA-based ... sustained cellular production of platelet-derived growth
factor-B (PDGF-B) protein as a treatment for ... Celsius. PDGF-B protein is a well known bone growth
mediator and is already used in several FDA ...
Caliper Life Sciences Reports Second Quarter 2009 Results
Achieved 8% overall organic revenue growth
compared to second quarter 2008 pro forma revenue:
Optical Imaging: 17% growth
(21% before currency impact)
Research: 1% growth
(5% before currency impact)
CDAS: 14% ...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
... to generate year-over-year quarterly revenue growth
on a constant currency basis and to deliver ... step in one of our targeted areas of future growth
by entering into a collaborative agreement with ... to $1.20, we're now projecting year-over-year growth
in full year adjusted diluted EPS of ...
Sanofi-aventis Announces Second Quarter 2009 Results
... in the second quarter of 2009
from Lantus(R) (up 26.0%), Lovenox(R) (up 13.3%) ... of Plavix(R) (up 9.6%)
of 18.4% for the Vaccines business excluding H5N1 contracts(2)
Net sales growth
of 5.4% in the U.S., 4.6% in Europe and 20.1% in ...
NeoGenomics Reports Second Quarter 2009 Results
During the second quarter, overall revenue growth
was impacted by seasonality in our Florida-based ... second quarter, and particularly with the rate of growth
of our business outside of the state of Florida," ... liquidity and flexibility in funding our growth
Robert Gasparini, the ...
Digitas Health Expands Adding Two Key Locations
... move is a strategic part of the agency's 2010 growth
plan. Digitas Health has experienced increased annual revenue growth
of approximately 50 percent in each of the last ...
Digitas Health has enjoyed a long period of growth
and accolades. The company's creative work was ...
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
... block tumor-related vascular endothelial growth
factor (VEGF). With its novel mechanism of ... VEGF expression necessary to maintain the growth
and function of normal blood vessels. Patients ... production of the protein vascular endothelial growth
factor (VEGF) in tumors. PTC discovered PTC299 ...
Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
... of naturally secreted embryonic proteins, growth
factors and contains the first naturally ... product, which contains Wnt proteins and other growth
factors important to hair follicle maintenance ... compounds containing bioactive Wnt increase hair growth
While additional clinical ...
PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
... in the development of our long-acting human growth
hormone candidate that has the potential to ... developing long-acting versions of human growth
hormone, interferon beta and erythropoietin, ... well as GLP-1. The company's long-acting human growth
hormone drug candidate, which is expected to ...
Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
guidelines on health claims in India is a growth
According to a Frost ... & Middle East, "The market has good scope of growth
the positive growth
of the Indian food processing industry in terms ...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
... of reported to adjusted (organic) sales growth
are on page 7.
Operating and pretax ... in the second quarter from global sales growth
initiatives and profit enhancement activities ... reaffirmed its full year 2009 organic sales growth
expectation in a low single digit range. This ...
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
... preclinical anti-VEGF (Vascular Endothelial growth
Factor) antibody program. Under the terms of the ... antibody program, targets the cancer-promoting growth
factor VEGF. Data presented at IBC's 5th Annual ... as Avastin(R) (bevacizumab) in inhibiting tumor growth
in a number of models of human cancers, including ...
Neogen Reports 16% Increase in Revenues
... ahead for us, and we will continue to execute the growth
strategies necessary to seize the opportunities." ... addition, we were pleased to see our percentage growth
in operating income exceed our percentage growth
in revenue for the fourth quarter as we continue ...
Schering-Plough Reports Financial Results for 2009 Second Quarter
... tough challenges - delivering operational sales growth
and reconciled earnings-per-share growth
for the second quarter," said Fred Hassan, ... second quarter of 2008, reflecting operational growth
of 4 percent and an unfavorable impact from ...
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
... & Sullivan:
Frost & Sullivan, the growth
Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, growth
Consulting and growth
Team Membership empower clients to create a ...
OpenQ Posts a 200% Revenue Growth in the First Half of 2009
... OpenQ announces solid revenue growth
for the first half of 2009 and is now serving 7 ... announced today a continuing trend of profitable growth
amidst global turmoil in the Life Sciences market. OpenQ posted a phenomenal 200% revenue growth
in the first half of 2009 as compared to the same ...
Essilor : First Half 2009 Revenue
... - Strong growth
in First-Half Revenue, up 9.4%
- Operating ... polarized lens in the United States.
- Firm growth
in entry-level products, where Essilor holds ... in instruments.
The strong 6% growth
from changes in the scope of consolidation ...
STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
2nd quarter growth
remained high at 9% (organic* 8%), but slowed ... with the very strong start of the year. Sales growth
over the first
half-year remained strong at 12% ... operations to a subsidiary in Switzerland.
was more moderate in Southern Europe (up 9%). In ...
China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
... year ago. The increase resulted
from significant growth
in the sales of new products, most of which were ... the Company's Shining-branded retail outlets, and growth
in the bulk
additive business. The Company's ... assistants contributed to the rapid revenue growth
from new products
through its customer-oriented ...
Gerresheimer Holds its own in Difficult Environment
... Plastics) at Prior Year Level
in the Pharma Business
- Sales Decline in ... This result was
mainly attributable to sales growth
for pharmaceutical packaging and systems,
with ... in focusing the business," Herberg adds.
for pharmaceutical products
Regardless of ...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... Prostate Cancer Therapeutics Market II-6
Rise in Prostate Cancer Incidences & Access to Modern
Therapeutics Foster growth
Table 2: New Incidences of Prostate ... II-8
Supportive Cancer Drugs Contribute to growth
Select FDA Approved Drugs for Palliative ...
ArborGen and Senesco Announce Wood Quality Results
... technology have shown significantly enhanced growth
rates in 3-year-old field trials.
Selected ... gravity, between the trees with the enhanced growth
attributes and untreated control trees. This is good news as fast tree growth
is often associated with lower wood quality.
PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
... for the company's long-acting CTP-enhanced human growth
hormone (hGH-CTP) and human erythropoietin ... two new patents covering CTP-enhanced human growth
hormone and erythropoietin represent another ... with hGH-CTP, its longer-acting version of human growth
hormone, later this year.
The issue date for ...
Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
... metabolism, proliferation, and DNA damage. Strong growth
in the future will be led by expansion of ... years are forecast to witness both the strong growth
for multi-targeted kinase inhibitors, and the ... to regroup to recalibrate and spread through new growth
Global sales of Gleevec are ...
Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
... deceleration in growth. Key factors slowing down growth
in the global prescription drugs market include ... and pharmacogenomics, which are spearheading growth
in the industry.
San ... slowdown in 2009 and 2010, with declines or flat growth
expected in mature markets such as the US, Japan, ...
UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases
... impacts of different chemical components. Once growth
in serum is accomplished, researchers will often ... so they decided to attempt myelination using the growth
medium they have spent years tweaking.
... while serum contains components that promote cell growth
it may also contain some that inhibit growth. ...
SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
... Frost and Sullivan
Frost & Sullivan, the growth
Consulting Company, partners with clients to accelerate their growth. The company's growth
Partnership Services, growth
Consulting and Career Best Practices empower ...
Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan
... is a smaller market, it is witnessing rapid growth
in terms of both new bio-diesel capacities coming ... bio-diesel, there are several strong drivers of growth
for both increased supply as well as demand. ... subsidies or tax exemption, will in turn spur growth
for the development of bio-diesel."
PTC Therapeutics Receives $2.6 Million in Government Grants
... of new blood vessels, and supports tumor growth
in patients with NF2. PTC299 is a novel, orally ... production of the protein vascular endothelial growth
factor (VEGF) in tumors, while sparing ... production of the protein vascular endothelial growth
factor, or VEGF, in tumors. PTC discovered ...
Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
... its existing development pipeline
and future growth
opportunities to a much larger audience of ... investment community are properly informed of
strategy and competitive advantages. We are ... healthcare
plan and the long-term, secular growth
opportunity in China," said Matthew
OpenQ is Awarded Prestigious Life Sciences Industry Award
... OpenQ wins the 2009 Global Pharmaceutical CRM growth
Strategy Leadership of the Year presented by ... the prestigious 2009 Global Pharmaceutical CRM growth
Strategy Leadership of the Year award, presented ... the company that has demonstrated an exceptional growth
strategy within the industry.
Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting
... such as follicle stimulating hormone, human growth
hormone, interferon beta, erythropoietin, Factor ... trial with our longer-acting version of human growth
hormone, signalling our transformation into a ... developing long-acting versions of human growth
hormone, interferon beta and erythropoietin, ...